Status:
COMPLETED
Mapping the MoA Behind GI Protection From Bif195
Lead Sponsor:
Chr Hansen
Conditions:
Reduction of Small Intestinal Ulceration Risk
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The trial will investigate effects of daily intake of the bacterial strain Bif195 or placebo when co-administered to once-daily oral intake of 300 mg of Acetylsalicylic Acid (ASA). The trial includes...
Detailed Description
Subjects will participate in the trial for a total duration of approximately 17 weeks including the run-in phase. Besides the screening visit, the trial will consist of 4 visits. After having given t...
Eligibility Criteria
Inclusion
- • Written informed consent
- Healthy and without any gastrointestinal discomfort/pain or other significant symptoms
- Age ≥ 18 and ≤ 40 years
- Willing to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial
Exclusion
- \-
Key Trial Info
Start Date :
June 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04448847
Start Date
June 8 2020
End Date
January 12 2021
Last Update
April 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark, 2900